Traumalix forte
Traumalix forte is a medicine authorised by Swissmedic under authorisation number 51379. The authorisation holder is Drossapharm AG. The medicinal product code is Synthetic medicines and the dispensing category is D: Supplied in pharmacies and drugstores after specialist advice, without a prescription. First authorisation was granted on 06 February 1991 and the authorisation is valid without a time limit. ATC code M02AA06 places the medicine in the group Topical products for joint and muscular pain.
| Authorisation number | 51379 |
|---|---|
| Name | Traumalix forte |
| Full name | Traumalix forte, Spray |
| Authorisation holder | Drossapharm AG |
| Medicinal product code | Synthetic medicines |
| Dispensing category | D · No prescription, with advice |
| ATC code | M02AA06 |
| First authorisation | 06 February 1991 |
| Authorisation validity | unlimited |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Traumalix forte, Spray | D | 06 February 1991 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 2 | 50 | ml | M02AA06 | 07.10.4. | D |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Traumalix forte authorised in Switzerland?
Yes. Traumalix forte is authorised by Swissmedic under authorisation number 51379, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Traumalix forte have?
Traumalix forte is in dispensing category D. Supplied in pharmacies and drugstores after specialist advice, without a prescription.
Who is the authorisation holder of Traumalix forte?
The authorisation holder is Drossapharm AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.